Editing Maryland (section)

===Biotechnology===
Maryland is a major center for [[life sciences]] research and development. With more than 400 biotechnology companies located there, Maryland is the fourth largest nexus in this field in the United States.<ref>{{cite web |url=http://marylandbiocenter.org/Bioscience%20of%20Maryland/Pages/factsandfigures.aspx |title=Maryland's Bioscience Environment: 2009 |access-date=August 19, 2011 |publisher=The Maryland Biotechnology Center |archive-url=https://web.archive.org/web/20110820175129/http://marylandbiocenter.org/Bioscience%20of%20Maryland/Pages/factsandfigures.aspx |archive-date=August 20, 2011 |url-status=dead }}</ref>

Institutions and government agencies with an interest in research and development located in Maryland include the [[Johns Hopkins University]], the [[Johns Hopkins Applied Physics Laboratory]], more than one campus of the [[University System of Maryland]], [[Goddard Space Flight Center]], the [[United States Census Bureau]], the [[National Institutes of Health]], the [[National Institute of Standards and Technology]], the [[National Institute of Mental Health]], the [[Walter Reed National Military Medical Center]], the federal [[Food and Drug Administration]], the [[Howard Hughes Medical Institute]], the [[Celera Genomics]] company, the [[J. Craig Venter Institute]], and [[AstraZeneca]] (formerly [[MedImmune]]).

Maryland is home to defense contractor [[Emergent BioSolutions]], which manufactures and provides an [[anthrax vaccine]] to U.S. government military personnel.<ref>{{cite news|title=Emergent BioSolutions Receives Orphan Drug Designation for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease|url=http://www.marketwatch.com/story/emergent-biosolutions-receives-orphan-drug-designation-for-biothrax-for-post-exposure-prophylaxis-of-anthrax-disease-2014-04-21|access-date=August 29, 2016|work=Marketwatch.com|publisher=Dow Jones & Company|date=April 21, 2014|archive-date=September 18, 2016|archive-url=https://web.archive.org/web/20160918193256/http://www.marketwatch.com/story/emergent-biosolutions-receives-orphan-drug-designation-for-biothrax-for-post-exposure-prophylaxis-of-anthrax-disease-2014-04-21|url-status=live}}</ref>